Recent CDC data show rising autism diagnoses in the US, driven by improved screening and broader criteria. A new study confirms that the MMR vaccine is not linked to autism, supporting the importance of evidence-based understanding amid ongoing debates.
Public claims that autism is suddenly spreading because of one obvious cause do not hold up against the evidence. The latest figures from the Centers for Disease Control and Prevention put autism prevalence at about 1 in 31 8-year-olds in 2022 across 16 U.S. communities, up from about 1 in 150 in 2000. But the CDC also stresses that these are surveillance estimates drawn from selected sites, not proof that autism has become five times more common in a biological sense. The agency’s network is designed to track patterns, compare communities and measure progress in early identification, and its data show large differences from place to place, from 1 in 103 in Texas to 1 in 19 in California.
The rise in diagnoses is widely understood to reflect broader awareness, changes in diagnostic criteria and earlier screening. What once might have been described as language delay, social immaturity or developmental delay is now more likely to trigger an autism evaluation, often between the ages of 2 and 4. Over time, the diagnosis has also expanded to include children with milder social-communication differences under the autism spectrum disorder umbrella. The CDC and the National Institute of Mental Health both note that autism is identified in all racial and ethnic groups, and that it is much more common in boys than girls.
A new study published in the Pediatric Infectious Diseases Journal adds further weight to the long-running conclusion that the measles, mumps and rubella vaccine is not linked to autism. Using data from the Cosmos electronic health record database, researchers examined more than 2.5 million U.S. children with linked birth-parent records and followed them from age 1 to age 8, or until an autism diagnosis or last recorded visit. Rather than simply comparing vaccinated and unvaccinated children, the authors used a landmark design that anchored analysis at set ages to reduce timing bias, and they adjusted for 29 potential confounders. The study found no increase in autism risk among children who received the first MMR dose between 11.5 and 24 months, and the result was similarly null in narrower age bands.
The strongest check on the method came from a negative control: the pneumococcal conjugate vaccine booster, given at 12 to 15 months, produced a similarly null result. That matters because there is no biological reason to expect the pneumococcal shot to affect autism risk; if it had shown a misleading association, that would have suggested the analysis was picking up bias rather than a real effect. The authors said their findings reinforce the existing evidence base on MMR safety. Still, as with all observational research, the study cannot rule out every unmeasured factor, and it is not designed to exclude a very small effect in a rare subgroup. Even so, for the U.S. population as a whole, the new analysis adds to the evidence that MMR vaccination in early childhood is not associated with autism.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
